• Notice: This site utilises 'cookies' for shopping and analytics, and by using it you agree to our Privacy Policy.
    This notice is designed to only be seen once on any particular device.

Clozapine Directory Icon  - Kings Pathology Printer Icon - Kings Pathology

Toxicology Overview / Directory

Test Icon  - Kings Pathology

Purpose of the test

Clozapine is an atypical antipsychotic used to treat schizophrenia resistant to conventional therapy. Because of the risk of agranulocytosis, white blood cell counts (WBC) are monitored weekly in the early stages of therapy and monthly thereafter. It is recommended that therapy is withheld if the WBC is less than 3,500 mm-3 and abandoned if the WBC falls below 3000 mm-3 or the granulocyte count below 1,500 mm-3.

Side-effects of clozapine include lethargy, hypersalivation, constipation and somnolence. There is a risk of hypo-tension and seizure at higher doses. A single dose of 300-400 mg may be life-threatening in a clozapine-naïve subject. Clozapine is metabolised by N-demethylation, hydroxylation and N-oxidation. The N-demethylated metabolite, nor-clozapine, is present in plasma at similar concentrations to the parent compound, but has a longer plasma half-life.

Plasma clozapine concentrations of 0.35 mg/L and above have been associated with a good response, with the risk of convulsions increasing above 1.0 mg/L.

PDF Icon  - Kings Pathology

Test PDF

Standard Kch Clozapine Request Form V2.pdf

notes Icon  - Kings Pathology

Sample Requirements

2mL of EDTA whole blood preferred. Serum or plasma can be used if required.

Transport Icon  - Kings Pathology

Storage and Transport

Please refrigerate (if possible) if not sending immediately. Send by first class post to:

Toxicology Unit

Top Floor, Bessemer Wing

King’s College Hospital

Denmark Hill

London

SE5 9RS

If possible, please COMPLETE (details can be completed electronically) & PRINT the request form above (Test PDF) and send as a hard copy (DO NOT SEND ELECTRONICALLY) with the sample. This will ensure all relevant information is available and will aid us in processing your test.

Important note for patients currently registered with the Clozaril Patient Monitoring Service (CPMS): A special request form is available to download below. Do not use this form if you are not registered with CPMS!

Transport Icon  - Kings Pathology

PDF Request Form

Download Clozapine Request Form

Time Icon  - Kings Pathology

Turnaround Time

Results are available within 2 working days of receipt in the laboratory.

Price Icon  - Kings Pathology

Price

Price available on application - please contact adrianturner1@nhs.net. Discounts could be available for significant workloads.

(for patients registered with the Clozaril® Patient Monitoring Service, CPMS or the Denzapine® Monitoring Service, DMS please contact the respective supplier for details of sample transport arrangements and assay cost)

Contact Icon  - Kings Pathology

Contacts

Clinical Advice & Interpretation

Dr Bob Flanagan

E robert.flanagan@nhs.net

T 020 3299 5881

Fax 020 3299 5888

Laboratory

Simon Handley

E simon.handley@nhs.net

T 020 3299 5883

F 020 3299 5888

Range Icon  - Kings Pathology

References

Bowskill S, Couchamn L, MacCabe J, Flanagan R. Plasma clozapine and norclozapine in relation to prescribed dose and other factors in patients aged 65 years and over: data from a therapeutic drug monitoring service, 1996–2010. Human Psychopharmacology: Clinical & Experimental, 2012.

Couchman L, Morgan P, Spencer E, Flanagan J. Plasma Clozapine, Norclozapine, and the Clozapine:Norclozapine Ratio in Relation to Prescribed Dose and Other Factors: Data From a therapeutic Drug monitoring Service, 1993-2007. Therapeutic Drug Monitoring, 2010.

Couchman L, Morgan P, Spencer E, Johnston A, Flanagan R. Plasma Clozapine and Norclozapine in Parients Prescribed Different Brands of Clozapine (Clozaril, Denzapine, Zaponex). Therapeutic Drug Monitoring, 2010.

Couchman L, Bowskill S, Handley S, Patel M, Flanagan R. Plasma clozapine and norclozapine in relation to prescribed dose and other factors in patients aged <18 years: Data from a Therapeutic Drug Monitoring service, 1994-2010. Early Intervention in Psychiatry, 2012; doi: 10.1111/j.1751-7893.2012.00374.x. [Epub ahead of print]

Flanagan RJ, Spencer E, Morgan P, Barnes T, Dunk L. Suspected clozapine poisoning in the UK/Eire, 1992–2003. Forensic Science International, 2005; 155:91-99.

Flanagan RJ. Therapeutic Monitoring of Antipsychotic Drugs. CPD Clinical Biochemistry, 2006.

Hiemke C et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry, 2011; 44: p195-235

Fisher DS et al. LC-MS/MS of some atypical antipsychotics in human plasma, serum, oral fluid and haemolysed whole blood. Forensic Science International, 2013 (epub ahead of print)

Fisher DS et al. Stability of some atypical antipsychotics in human plasma, haemolysed whole blood, oral fluid, human serum and calf serum. Forensic Science International, 2013 (epub ahead of print)

Fisher DS et al. Plasma, Oral Fluid, and Whole Blood Distribution of Antipsychotics and Metabolites in Clinical Samples. Therapeutic Drug Monitoring, 2013 (epub ahead of print)

Close Go to Tests page